Key result
Prophylactic treatment with low-molecular-weight heparin and fondaparinux showed a consistent 50% reduction in venous thromboembolism events in acutely ill medical patients.
Why the study?
Does thromboprophylaxis with LMWH, UFH, or fondaparinux prevent venous thromboembolism in acutely ill medical patients?
Does thromboprophylaxis with LMWH, UFH, or fondaparinux prevent venous thromboembolism in acutely ill medical patients?
Effect estimate: 50% reduction
Prophylactic treatment with LMWH, UFH, or fondaparinux for 2 weeks is recommended to reduce the risk of venous thromboembolism in acutely ill medical patients.
No takes yet. Share an insight, caveat, or question.
May support prophylaxis with LMWH or fondaparinux in medical inpatients; leaves open optimal agent, duration, and net benefit.
Leizorovicz et al. (2004) conducted a review in Venous thromboembolism. Low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux was evaluated on Venous thromboembolism (VTE) events (50% reduction). Prophylactic treatment with low-molecular-weight heparin and fondaparinux showed a consistent 50% reduction in venous thromboembolism events in acutely ill medical patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: